{"id":538790,"date":"2021-09-15T16:04:12","date_gmt":"2021-09-15T20:04:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/"},"modified":"2021-09-15T16:04:12","modified_gmt":"2021-09-15T20:04:12","slug":"profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/","title":{"rendered":"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature"},"content":{"rendered":"<h2>\nPublication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">WALTHAM, Mass., Sept.  15, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PPXJBkoneMcgJkHO_JnF15lTZj8F4l3UDn2ddOjAuHxuTRtSbL4lVMt3mZo1JqY1GOZUh_xXGR3SA4sfZZh2CrgbgQBbFCvpGqpI1oFmFTE=\" rel=\"nofollow noopener\" target=\"_blank\">Entasis Therapeutics<\/a> Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of a profile of the company\u2019s ETX0462 candidate in the prestigious scientific journal <em>Nature<\/em> (DOI: 10.1038\/s41586-021-03899-0). The article, titled \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2SMZl-0hvVAOafysD1IHJaf2GFdlDYad0wzLl10Iw2hgABvlbOxqkPRGzVNrCam8vnl2r0s0K6ChrgQ1zsZyOoOkcstbU1psislAylyCzoLz0cpUxsmRUehg23Wf6ns4UeNcjEu3f9UnKzSzJXqxHfO9eVd4SvNmr-pauAn59FX9YWnlHcTl_TRTgq0VN9wi\" rel=\"nofollow noopener\" target=\"_blank\"><em>Rational design of a new antibiotic class for drug-resistant infections<\/em><\/a>\u201d describes the discovery and preclinical profile of ETX0462, which could become the first of a new class of antibiotics for multidrug-resistant (MDR) Gram-negative and biothreat infections.<\/p>\n<p align=\"justify\">The manuscript details the discovery of ETX0462, highlighting the importance of concurrent optimization of biochemical potency and drug penetration into the bacterial cells to identify structural elements critical for antimicrobial activity against multiple contemporary MDR Gram-negative and biothreat bacterial pathogens, including MDR <em>Pseudomonas. <\/em>Thanks to its innovative chemical design, the activity of ETX0462 is unaffected by all four Ambler classes of \u03b2-lactamases. Furthermore, ETX0462\u2019s ability to permeate bacterial cells through multiple porins and inhibition of multiple penicillin-binding proteins (PBP) enzyme subtypes, results in low propensity for resistance emergence.<\/p>\n<p align=\"justify\">\u201cTo our knowledge, the novel lead optimization approach which led to ETX0462 is a first in antibiotic drug discovery,\u201d commented Ruben Tommasi, Chief Scientific Officer at Entasis. \u201cLeveraging our platform of permeation and biochemical assays, we developed detailed knowledge of factors affecting accumulation in Gram-negative pathogens as well as PBP target potency. We\u2019re excited to see these efforts culminate in the development of ETX0462. We continue to leverage our innovative drug discovery platform to design additional preclinical candidates against high-priority bacterial pathogens.\u201d<\/p>\n<p align=\"justify\">\u201cI would like to congratulate the authors on the publication of this profile of ETX0462 in the prestigious scientific journal, <em>Nature<\/em>,\u201d stated Manos Perros, Chief Executive Officer at Entasis. \u201cWith topline data from the ongoing ATTACK pivotal trial for SUL-DUR expected in early 4th quarter, zoliflodacin in Phase 3 and ETX0282CPDP having completed an initial Phase 1, our R&amp;D team has once again succeeded in translating excellent science to promising innovation for patients suffering from bacterial infections.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Entasis Therapeutics Inc.<\/strong><br \/>\n        <br \/>Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting <em>Acinetobacter baumannii<\/em> infections), zoliflodacin (targeting <em>Neisseria gonorrhoeae<\/em> infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting <em>Pseudomonas<\/em> infections). For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oaxKbokLq11gMar63c0dSsp0W9SDtiX2-xuZyaY8Frs4pYhIomFZvo-Yzzld3_3J5_6TYa9b9Z1crM1AKusF_A==\" rel=\"nofollow noopener\" target=\"_blank\">www.entasistx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About ETX0462<\/strong><br \/>\n        <br \/>ETX0462 is a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens including, <em>P. aeruginosa, K. pneumoniae, S. maltophilia, E. coli, B. anthracis, Y. pestis, F. tularensis and Burkholderia spp<\/em>. Similar to \u03b2-lactam antibiotics, ETX0462 inhibits penicillin-binding proteins which are essential for bacterial cell wall biosynthesis, however, unlike \u03b2-lactam antibiotics, ETX0462 is unaffected by \u03b2-lactamase mediated resistance. ETX0462 is supported by CARB-X.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:20%;width:20%;min-width:20%\">\n            <strong>Company Contact<br \/><\/strong>Kyle Dow<br \/>Entasis Therapeutics<br \/>(781) 810-0114<br \/><a href=\"mailto:kyle.dow@entasistx.com\" rel=\"nofollow noopener\" target=\"_blank\">kyle.dow@entasistx.com<\/a><strong><br \/><\/strong><\/td>\n<td style=\"max-width:80%;width:80%;min-width:80%\">\n            <strong>Investor Contact<\/strong><br \/>\n            <br \/>Bruce Mackle<br \/>LifeSci Advisors<br \/>(929) 469-3859<br \/><a href=\"mailto:bmackle@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjdiNGU4NjctYzgzNy00OWE5LTk5ZDEtYjViMTU5Mjg4YzY0LTExMDc0MjQ=\/tiny\/Entasis-Therapeutics-Holdings-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens WALTHAM, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) &#8212; Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of a profile of the company\u2019s ETX0462 candidate in the prestigious scientific journal Nature (DOI: 10.1038\/s41586-021-03899-0). The article, titled \u201cRational design of a new antibiotic class for drug-resistant infections\u201d describes the discovery and preclinical profile of ETX0462, which could become the first of a new class of antibiotics for multidrug-resistant (MDR) Gram-negative and biothreat infections. The manuscript details the discovery of ETX0462, highlighting the importance of concurrent optimization of biochemical potency and drug &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-538790","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens WALTHAM, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) &#8212; Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of a profile of the company\u2019s ETX0462 candidate in the prestigious scientific journal Nature (DOI: 10.1038\/s41586-021-03899-0). The article, titled \u201cRational design of a new antibiotic class for drug-resistant infections\u201d describes the discovery and preclinical profile of ETX0462, which could become the first of a new class of antibiotics for multidrug-resistant (MDR) Gram-negative and biothreat infections. The manuscript details the discovery of ETX0462, highlighting the importance of concurrent optimization of biochemical potency and drug &hellip; Continue reading &quot;Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-15T20:04:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature\",\"datePublished\":\"2021-09-15T20:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/\"},\"wordCount\":521,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/\",\"name\":\"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=\",\"datePublished\":\"2021-09-15T20:04:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/","og_locale":"en_US","og_type":"article","og_title":"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature - Market Newsdesk","og_description":"Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens WALTHAM, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) &#8212; Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of a profile of the company\u2019s ETX0462 candidate in the prestigious scientific journal Nature (DOI: 10.1038\/s41586-021-03899-0). The article, titled \u201cRational design of a new antibiotic class for drug-resistant infections\u201d describes the discovery and preclinical profile of ETX0462, which could become the first of a new class of antibiotics for multidrug-resistant (MDR) Gram-negative and biothreat infections. The manuscript details the discovery of ETX0462, highlighting the importance of concurrent optimization of biochemical potency and drug &hellip; Continue reading \"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-15T20:04:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature","datePublished":"2021-09-15T20:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/"},"wordCount":521,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/","name":"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=","datePublished":"2021-09-15T20:04:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjc1MyM0NDA3NjgzIzIwOTU4NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profile-of-entasis-therapeutics-etx0462-candidate-published-in-the-journal-nature\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=538790"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538790\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=538790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=538790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=538790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}